Medannex seeking COVID-19 development partnering for novel antibody therapy
Medannex are urgently seeking partners to help expedite the development of a novel antibody (MDX-124) which may help in the fight against COVID-19. MDX-124 targets annexin-A1, a key component of the immune system. Annexin-A1 facilitates multiple steps